Chung HC, Saada-Bouzid E, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer 2024 Jun 21. doi: 10.1002/cncr.35387.
PMID: 39031824